Our Science

Breakthrough Dual-Action Mechanism

Addressing the fundamental limitations of current angina therapies

CR-0305: Demonstrates High Potency Over Isosorbide Mononitrate

Dramatic potency over established therapies. In direct ex vivo comparisons, CR-0305 relaxes pre-contracted human coronary arteries at much lower concentrations than isosorbide mononitrate

Dose-response curve comparing CR-0305 vs isosorbide mononitrate – 23× greater vasodilatory potency in ex vivo studies

CR-0305 achieves half-maximal relaxation (IC50) at just 3.0µM, compared to 67.8µM for isosorbide mononitrate. Superior potency means the potential to deliver more consistent, effective relief for patients who fail current nitrate therapies

CR-0305 demonstrates an excellent safety profile in human cells

Human cells that line blood vessels were exposed to CR-0305 and related Coeurative compounds to assess their safety. For comparison, cells were also treated with a harmless control and with doxorubicin, a known toxic agent.

In every case, the cells treated with CR-0305 and other Coeurative compounds stayed healthy and active, showing no difference from untreated cells even after 18 hours.

By contrast, the toxic control caused a clear drop in cell health, underscoring the strong safety profile of CR-0305 and its related compounds.

Additional Animal Data as Well as Human Cell Data Available Under CDA